2-acetylamino-4-chloro-5-ethoxycarbonylpyrimidine | 84331-98-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-acetylamino-4-chloro-5-ethoxycarbonylpyrimidine
• 英文别名: Ethyl 2-acetamido-4-chloropyrimidine-5-carboxylate
• CAS: 84331-98-6
• 化学式: C₉H₁₀ClN₃O₃
• 分子量: 243.65
• InChiKey: RRSQBAHSZIHYTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  81.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-acetylamino-4-chloro-5-ethoxycarbonylpyrimidine 在 sodium hydroxide 、 sodium 、 氯甲酸乙酯 、 三乙胺 作用下， 以 甲醇 、 水 为溶剂， 反应 1.5h， 生成 2-氨基-N-(1-乙基-4-哌啶基)-4-甲氧基-5-嘧啶甲酰胺
  参考文献：
  名称：

  Dostert; Imbert; Ancher, European Journal of Medicinal Chemistry, 1982, vol. 17, # 5, p. 437 - 444

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-5-乙氧羰基-4-羟基嘧啶 在 溶剂黄146 、 三氯氧磷 作用下， 反应 34.0h， 生成 2-acetylamino-4-chloro-5-ethoxycarbonylpyrimidine
  参考文献：
  名称：

  [EN] IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE
  [FR] DÉRIVÉS D'IMIDAZO[1,2-A]PYRIDINE SERVANT D'INHIBITEURS D'IRAK4 ET LEUR UTILISATION DANS LE TRAITEMENT D'UNE MALADIE

  摘要：

  本公开涉及公式(I)的咪唑[1,2-a]吡啶衍生物或其药学上可接受的盐，公式(I)中所有变量如规范所定义，能够调节IRAK4活性。本公开进一步提供其制备方法，医药用途，特别是在治疗和管理包括炎症性疾病、自身免疫性疾病、癌症、心血管疾病、中枢神经系统疾病、皮肤疾病、眼科疾病和状况以及骨疾病等疾病或障碍中的应用。

  公开号：

  WO2022140425A1

文献信息

• [EN] IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] DÉRIVÉS D'IMIDAZO[1,2-A]PYRIDINE SERVANT D'INHIBITEURS D'IRAK4 ET LEUR UTILISATION DANS LE TRAITEMENT D'UNE MALADIE
  申请人：BIOGEN MA INC

  公开号：WO2022140425A1

  公开（公告）日：2022-06-30

  This disclosure relates to imidazo[ 1,2-a]pyridinyl derivatives of formula (I), or pharmaceutically acceptable salts thereof, Formula (I) in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The disclosure further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

  本公开涉及公式(I)的咪唑[1,2-a]吡啶衍生物或其药学上可接受的盐，公式(I)中所有变量如规范所定义，能够调节IRAK4活性。本公开进一步提供其制备方法，医药用途，特别是在治疗和管理包括炎症性疾病、自身免疫性疾病、癌症、心血管疾病、中枢神经系统疾病、皮肤疾病、眼科疾病和状况以及骨疾病等疾病或障碍中的应用。
• Synthesis, Characterization, and<i>In Vitro</i>Antimicrobial Activity of a New Class of 7-Substituted Amino-2-phenyl-3H-pyrimido[4,5-<i>d</i>]pyrimidin-4-one
  作者：B. Surendra Reddy、A. Babul Reddy、G. Ramachandra Reddy、P. Raveendra Reddy

  DOI：10.1002/jhet.1542

  日期：2013.7

  A new class of pyrimido pyrimidine derivatives that exhibitsin vitro antimicrobial activity was synthesized. The protection of amino group in the compound 1 with acetic anhydride, followed by the reaction with POCl3, gave 3. The reaction of 3 with different substituted phenyl methanediamine in dry TEA under inert atmosphere led to the formation of 4. Deprotection of 4 followed by refluxion with different acid chlorides yielded title compounds 6a, 6b, 6c, 6d, 6e, 6f, 6g, 6h, 6i, 6j, 6k, 6l, 6m in good yields. The identities of these compounds were confirmed following elemental analysis, IR, 1H, 13C NMR, and mass spectral studies. All the title compounds exhibited pronounced in vitro antibacterial and antifungal activities.
• DOSTERT, P.;IMBERT, T.;ANCHER, J. F.;LANGLOIS, M.;BUCHER, B.;MOCQUET, G., EUR. J. MED. CHEM.-CHIM. THER., 1982, 17, N 5, 437-444
  作者：DOSTERT, P.、IMBERT, T.、ANCHER, J. F.、LANGLOIS, M.、BUCHER, B.、MOCQUET, G.

  DOI：——

  日期：——
• IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
  申请人：Biogen MA Inc.

  公开号：EP3990454A1

  公开（公告）日：2022-05-04
• [EN] IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] DÉRIVÉS D'IMIDAZO[1,2-A]PYRIDINYLE ET LEUR UTILISATION DANS LE TRAITEMENT D'UNE MALADIE
  申请人：BIOGEN MA INC

  公开号：WO2020263980A1

  公开（公告）日：2020-12-30

  This invention relates to Imidazo[l,2-a]pyridinyl Derivatives of formula (I), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.